What it is
Adipotide is a preclinical peptidomimetic developed for obesity research. It was studied for targeting adipose-tissue vasculature, but human development was discontinued because of kidney toxicity concerns.
Evidence boundary
Preclinical / discontinued. Do not present a human dosing schedule as established fact.
Trial evidence
No verified human trial found.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 250 mcg | 5 U (0.05 mL) | Once daily | 1.75 mg/week |
| Weeks 3–4 | 500 mcg | 10 U (0.1 mL) | Once daily | 3.5 mg/week |
| Weeks 5–6 | 750 mcg | 15 U (0.15 mL) | Once daily | 5.25 mg/week |
| Weeks 7–8 (target max) | 1 mg | 20 U (0.2 mL) | Once daily | 7 mg/week |
Weeks 1–2 (titration)
- Dose
- 250 mcg
- Draw / measure
- 5 U (0.05 mL)
- Frequency
- Once daily
- Weekly total
- 1.75 mg/week
Weeks 3–4
- Dose
- 500 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Weeks 5–6
- Dose
- 750 mcg
- Draw / measure
- 15 U (0.15 mL)
- Frequency
- Once daily
- Weekly total
- 5.25 mg/week
Weeks 7–8 (target max)
- Dose
- 1 mg
- Draw / measure
- 20 U (0.2 mL)
- Frequency
- Once daily
- Weekly total
- 7 mg/week
Weekly totals apply only during the active phase.
Titration rules
- Cautious daily titration (subcutaneous, once daily):
- Weeks 1–2 (titration): 250 mcg/day. Start conservatively; monitor for renal signs.
- Weeks 3–4: 500 mcg/day if tolerated.
- Weeks 5–6: 750 mcg/day if tolerated.
- Weeks 7–8 (target max): 1000 mcg (1 mg) /day. Do not exceed.
- Cycle: 4–8 weeks maximum. Extend only with extreme caution due to preclinical renal effects.
- Timing: Once daily at any consistent time; rotate injection sites.
- Monitoring: Consider periodic kidney function assessment for any cycle beyond 4 weeks.
Cycle length and breaks
Monitoring: Consider periodic kidney function assessment for any cycle beyond 4 weeks.
What to monitor
- Kidney toxicity concerns in preclinical work
- Injection-site reactions
Practical rules
- Do not use animal-model dosing as human guidance.
- Do not present weight-loss numbers as expectations.
- Rotate sites.